Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00649207 · ClinicalTrials.gov registry record · Phase 1

A Phase I Study of ABT-888 in Combination With Conventional Whole Brain Radiation Therapy (WBRT) in Cancer Patients With Brain Metastases

A Phase 1 study of Neoplasm Metastasis and Central Nervous System Diseases, sponsored by AbbVie (prior sponsor, Abbott).

Completed
Registry status
Phase 1
Development phase
80
Enrollment target
9
Study locations

NCT00649207: Completed Phase 1 study of Neoplasm Metastasis and Central Nervous System Diseases, sponsored by AbbVie (prior sponsor, Abbott).

NCT00649207 is a Phase 1 study of Neoplasm Metastasis and Central Nervous System Diseases that has completed, run by AbbVie (prior sponsor, Abbott). The registered enrollment target is 80 participants, below the 414-participant average among 41 other Neoplasm Metastasis trials with a reported enrollment target (81% lower). The trial reports 9 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00649207, a Phase 1 study of Neoplasm Metastasis and Central Nervous System Diseases, has completed, sponsored by AbbVie (prior sponsor, Abbott).

COMPLETED
Registry status
Phase 1
Development phase
80 participants
Enrollment target
9
Study locations

Study Summary

This Phase I clinical trial is studying the side effects and best dose of ABT-888 when given together with Whole Brain Radiation Therapy (WBRT) in treating patients with brain metastases.

Conditions Studied

Neoplasm Metastasis Central Nervous System Diseases Brain Neoplasms Brain Diseases Nervous System Neoplasms

Interventions

  • DRUG ABT-888
  • RADIATION Whole Brain Radiation Therapy

Study Locations (9)

Other

  • Site Reference ID/Investigator# 18542 - Toronto
  • Site Reference ID/Investigator# 46322 - Ponce

Georgia

  • Site Reference ID/Investigator# 8334 - Atlanta

Illinois

  • Site Reference ID/Investigator# 52462 - Chicago

Kansas

  • Site Reference ID/Investigator# 24483 - Kansas City

Maryland

  • Site Reference ID/Investigator# 7180 - Baltimore

Michigan

  • Site Reference ID/Investigator# 19021 - Detroit

Pennsylvania

  • Site Reference ID/Investigator# 6344 - Philadelphia

Wisconsin

  • Site Reference ID/Investigator# 6653 - Madison

Trial Details

FieldValue
Enrollment Target 80 participants
Start Date 2008-03
Est. Completion 2013-03
Phase Phase 1
AbbVie (prior sponsor, Abbott)

88 total trials

What the finished NCT00649207 record still lists

NCT00649207 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, below the 414-participant average among 41 other Neoplasm Metastasis trials with a reported enrollment target (81% lower).

The record links to 5 conditions, with Neoplasm Metastasis appearing as the primary indexed condition, and to 2 interventions - of which ABT-888 is the first listed.

NCT00649207 lists 9 locations in 8 states (Other, Georgia, Illinois).

Frequently Asked Questions

What is clinical trial NCT00649207 about?

NCT00649207 is a clinical study titled "A Phase I Study of ABT-888 in Combination With Conventional Whole Brain Radiation Therapy (WBRT) in Cancer Patients With Brain Metastases". This Phase I clinical trial is studying the side effects and best dose of ABT-888 when given together with Whole Brain Radiation Therapy (WBRT) in treating patients with brain metastases.

What is the current status of trial NCT00649207?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 80 participants. The study started on 2008-03. Estimated completion is 2013-03.

What conditions does trial NCT00649207 study?

This clinical trial studies the following conditions: Neoplasm Metastasis, Central Nervous System Diseases, Brain Neoplasms, Brain Diseases, Nervous System Neoplasms.

What interventions are being tested in trial NCT00649207?

The interventions under investigation include: ABT-888 (DRUG), Whole Brain Radiation Therapy (RADIATION).

Who is sponsoring clinical trial NCT00649207?

This trial is sponsored by AbbVie (prior sponsor, Abbott), which has 88 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00649207 being conducted?

This trial has 9 study locations across Georgia, Illinois, Kansas, Maryland, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Neoplasm Metastasis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00649207's enrollment target sits among peer trials

80 26th of 41 higher than 15 of 41 other Neoplasm Metastasis trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Neoplasm Metastasis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01243931 · 80 participants · NA

    Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy

  • NCT01659203 · 80 participants · Phase 1

    Proton or Photon RT for Retroperitoneal Sarcomas

  • NCT01803451 · 80 participants · Early Phase 1

    Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass

  • NCT01964859 · 80 participants · Phase 2

    Feasibility Study for Fibroblast Autologous Skin Grafts

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT00649207, the US trial registry maintained by the National Library of Medicine. NCT00649207 (small enrollment · multi site footprint · completed) retrieved and formatted by PlainTrial, see methodology.